Dexcom to Showcase Transformational Impact of Dexcom CGM Technology at the EASD 2024 Conference Symposium
-
Dexcom EASD Symposium brings together expert panellists from across
Europe to explore the transformational effects of Dexcom CGM on clinical practice. - With the most extensive clinical data and evidence, Dexcom is the most experienced partner in Automatic Insulin Delivery (AID)1.
- Studies show the potential for Dexcom CGM to support therapy de-escalation and optimise diabetes management in Type 2 diabetes.5,6,8
“I'm looking forward to chairing this panel of colleagues from across
Dexcom: The most experienced AID partner1
Dexcom’s CGM technology is the preferred choice for AID among healthcare professionals2, powering more AID systems than any other CGM brand1. Supported by the most extensive clinical data and evidence, patients using Dexcom-powered AID systems experience an average of 2.6 more hours in range per day*,3-4.
"Our commitment to innovation and excellence in diabetes management is unmatched, and our partnerships in advancing AID technology are a testament to that leadership. We’re not only shaping the future of diabetes care—we’re driving it forward with relentless passion and purpose,” said Jake Leach, Executive Vice President and Chief Operating Officer at Dexcom. “At the heart of our mission is our unwavering commitment to the diabetes community. Every decision we make is driven by our dedication to improving their lives and empowering them to manage diabetes with confidence."
With hundreds of thousands of users now connected to insulin pumps, pens, and digital health apps, Dexcom is the undisputed leader in CGM connectivity1.
This year, Dexcom has expanded G7 sensor connectivity, making it compatible globally with the Tandem t:slim X2 with Control IQ technology, and in the
Dexcom CGM: Optimising Type 2 Diabetes Management and Supporting Therapy De-Escalation
In one recent study, to be discussed during the Dexcom symposium,
"Studies consistently demonstrate the profound impact Dexcom CGM has on managing Type 2 diabetes," said Alex Moussa, SVP and GM, Dexcom EMEA & LATAM. "Across Europe, we're also seeing long-term cost savings for healthcare systems. As pioneers in real-time CGM, we're excited about how innovations like Dexcom ONE+ can further benefit healthcare systems and enhance patient lives."
Recent data from the Danish Steno2Tech trial revealed that twice as many Dexcom CGM users, compared to those using traditional blood glucose monitoring, met their HbA1c targets6. For insulin-treated Type 2 patients with poor glycaemic control, adding CGM significantly improved outcomes without increasing healthcare provider hours6. This better glycaemic control is linked to improved long-term health, fewer complications7, and potential for therapy de-escalation, particularly in older populations8.
Dexcom’s symposium ‘Thinking together: learnings from 3-real life cases to improve diabetes management and transform your clinical practice with CGM’, will take place on Monday 9th September, 1300 – 1430 CEST, Mumbai Hall, at the EASD 2024Conference in
About DexCom, Inc.
DexCom, Inc. empowers people to take control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in
*Results obtained with Dexcom G6 CGM with Tandem t:slim X2
1 Dexcom data on file 2024. 2 2023 survey amongst HCPs in 8 markets globally, N=291. 3 Brown SA, et al. N Engl J Med 2019;381(18):1707-17. 4 Battelino T, et al. Diabetes Care. 2019;42(8):1593-1603. 5 Clark, et al. Diabetes Technology and Therapeutics. 2024;doi:10.1089/dia.2023.0612 6 Lind, M et al. Diabetes Care. 2024;10.2337/dc23-2194. 7 DCCT trial: Diabetes Control and Complications Trial (DCCT). Diabetes Care. 1987 Jan-Feb;10(1):1-19. 8 Ajjan RA, et al. Nature Reviews Endo. 2024;20:426-440.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904210792/en/
Media Contact:
Gemma McDonald
+44 (0) 7552 368398
gemma.mcdonald@dexcom.com
Investor Relations Contact:
Sean Christensen
858-203-6657
sean.christensen@dexcom.com
Source: DexCom, Inc.